DexCom, Inc. and its peers
1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.
Companies in the group
Up to 12. Remove or re-base from the table's column heads.
Keep this group
Save it for yourself or, in a team, for everyone in it.
Suggested peers of DexCom, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Mettler-Toledo International Inc.MTD · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $32.5 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32.5 B (Oct 21, 2026) · revenue $4.0 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Quest Diagnostics IncorporatedDGX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $27.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $27.8 B (Oct 30, 2026) · revenue $11.0 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Labcorp Holdings Inc.LH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $26.3 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26.3 B (Oct 22, 2026) · revenue $14.0 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Guardant Health, Inc.GH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $24.1 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24.1 B (Oct 28, 2026) · revenue $982 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Illumina, Inc.ILMN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $40.7 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $40.7 B (Oct 26, 2026) · revenue $4.3 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- IDEXX Laboratories, Inc.IDXX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $41.5 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $41.5 B (Oct 6, 2026) · revenue $4.3 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- Waters CorporationWAT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $44.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $44.8 B (Oct 27, 2026) · revenue $3.2 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- IQVIA Holdings Inc.IQV · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $45.1 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $45.1 B (Oct 27, 2026) · revenue $16.3 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Medpace Holdings, Inc.MEDP · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $19.0 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19.0 B (Oct 30, 2026) · revenue $2.5 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Agilent Technologies, Inc.A · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $48.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48.8 B (Oct 19, 2026) · revenue $6.9 B (year to October 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Revvity, Inc.RVTY · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.6 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.6 B (Oct 23, 2026) · revenue $2.9 B (year to December 2025)96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Charles River Laboratories International, Inc.CRL · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.2 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.2 B (Oct 28, 2026) · revenue $4.0 B (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | DexCom, Inc.base DXCM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|
| Size | ||
| Market cap (Better neither way: ranked highest first) | $29.9 BOct 22, 2026 · Market dataonly one with it | $29.9 B— |
| Revenue (Better neither way: ranked highest first) | $4.7 BFY2025 · SEConly one with it | $4.7 B— |
| Net income (Higher is better) | $836 MFY2025 · SEConly one with it | $836 M— |
| Employees (Better neither way: ranked highest first) | 11,100December 31, 2025 · Profileonly one with it | 11,100— |
| Growth | ||
| Revenue growth (Higher is better) | +15.6%FY2025 · SEConly one with it60th72nd | +15.6%— |
| Revenue growth, 3 years a year (Higher is better) | +17.0%FY2025 · SEConly one with it68th82nd | +17.0%— |
| Earnings per share growth (Higher is better) | +47.2%FY2025 · SEConly one with it75th80th | +47.2%— |
| Margins and returns | ||
| Gross margin (Higher is better) | 60.1%FY2025 · SEConly one with it53rd74th | 60.1%— |
| Operating margin (Higher is better) | 19.6%FY2025 · SEConly one with it88th85th | 19.6%— |
| Net margin (Higher is better) | 17.9%FY2025 · SEConly one with it89th87th | 17.9%— |
| Free cash flow margin (Higher is better) | 23.1%FY2025 · SEConly one with it92nd91st | 23.1%— |
| Return on equity (Higher is better) | 34.5%FY2025 · SEConly one with it95th93rd | 34.5%— |
| Valuation | ||
| P/E ratio (Better neither way: ranked highest first) | 30.2×price Oct 22, 2026 · Market dataonly one with it51st72nd | 30.2×— |
| Price to sales (Better neither way: ranked highest first) | 5.9×price Oct 22, 2026 · Market dataonly one with it61st80th | 5.9×— |
| Price to book (Better neither way: ranked highest first) | 10.9×price Oct 22, 2026 · Market dataonly one with it85th90th | 10.9×— |
| Free cash flow yield (Higher is better) | 3.6%price Oct 22, 2026 · Market dataonly one with it81st57th | 3.6%— |
| Financial strength | ||
| Interest cover (Higher is better) | 63.8×FY2025 · SEConly one with it99th97th | 63.8×— |
| Scorecard | ||
| Scorecard (Higher is better) | 18 of 24FY2025 · Scorecardonly one with it | 75% passed— |
| Valuation checks (Higher is better) | 1 of 6FY2025 · Scorecardonly one with it | 17% passed— |
| Growth checks (Higher is better) | 6 of 6FY2025 · Scorecardonly one with it | 100% passed— |
| Profitability checks (Higher is better) | 5 of 5FY2025 · Scorecardonly one with it | 100% passed— |
| Financial health checks (Higher is better) | 4 of 4FY2025 · Scorecardonly one with it | 100% passed— |
| Shareholder returns checks (Higher is better) | 2 of 3FY2025 · Scorecardonly one with it | 67% passed— |
| Ownership | ||
| Held by institutions (Better neither way: ranked highest first) | 98.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 98.2%— |
| Institutions holding (Better neither way: ranked highest first) | 1,0542026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 1,054— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +8.2 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | +8.2 pp— |
| Dividends | ||
| Shareholder yield (Higher is better) | 1.7%FY2025 · SEConly one with it43rd30th | 1.7%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = DexCom, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| DexCom, Inc. | 19.6%FY2025 | 88th percentile in Healthcaremedian -7.7%, 674 companies | 85th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | DexCom, Inc. |
|---|---|
| 2025 | $4.7 BSEC |
| 2024 | $4.0 BSEC |
| 2023 | $3.6 BSEC |
| 2022 | $2.9 BSEC |
| 2021 | $2.4 BSEC |
| 2020 | $1.9 BSEC |
| 2019 | $1.5 BSEC |
| 2018 | $1.0 BSEC |
| 2017 | $719 MSEC |
| 2016 | $573 MSEC |
| 2015 | $402 MSEC |
| 2014 | $259 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.